The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Therapy"
DOI: 10.1007/s13300-020-00981-0
Abstract: Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the treatment algorithm owing to glycaemic efficacy, weight reduction and favourable cardiovascular… read more here.
Keywords: glp; gip; clinical trials; glp receptor ... See more keywords
80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-80-lb
Abstract: Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for type 2 diabetes (T2D). Efficacy and safety of TZP vs. placebo (PBO) was assessed in people with T2D as an add-on to titrated… read more here.
Keywords: company; lilly company; eli lilly; gip glp ... See more keywords
Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2022 at "Endokrynologia Polska"
DOI: 10.5603/ep.a2022.0029
Abstract: The incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are responsible for up to 65% of postprandial insulin secretion. Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist in the… read more here.
Keywords: glp; dual gip; gip; gip glp ... See more keywords